Relmada Therapeutics Announces Proposed Public Offering of Common Stock
CORAL GABLES, Fla., Dec. 08, 2021 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases…
Pharmaceuticals, Biotechnology and Life Sciences
CORAL GABLES, Fla., Dec. 08, 2021 (GLOBE NEWSWIRE) — Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases…
Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs.…
WOBURN, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of…
Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with…
The wearABLe study did not demonstrate non-inferiority of abalo-TDS to TYMLOS®Lumbar spine BMD at 12 months vs. baseline for abalo-TDS…
BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) — Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) announced it will host…
JSP191 is well tolerated with no treatment-related adverse events in dose-escalation studySingle-agent conditioning with JSP191 is associated with engraftment, immune…
WALTHAM, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology…
ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company focused on developing and…
NEW YORK, NY, Dec. 08, 2021 (GLOBE NEWSWIRE) — Sugarmade, Inc. (OTC Pink: SGMD) (“Sugarmade”, “SGMD” or the “Company”) an…